Role of neuroimmune communication via the gut-brain axis in the pathogenesis of hepatic encephalopathy

Yong LIN; Jiongfen LI; Feiyan LI; Yuanqin DU; Meiyan LIU; Minggang WANG; Fuli LONG; Na WANG; Dewen MAO

doi:10.12449/JCH241224

Volume 40 Issue 12

Dec. 2024

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2024 > 40(12): 2518-2523

PDF( 1541 KB)

Role of neuroimmune communication via the gut-brain axis in the pathogenesis of hepatic encephalopathy

DOI: 10.12449/JCH241224

1.
Graduate School of Guangxi University of Chinese Medicine，Nanning 530200，China
2.
Department of Hepatology，The First Affiliated Hospital of Guangxi University of Chinese Medicine，Nanning 530023，China

Research funding:

National Natural Science Foundation of China (82260907);

National Natural Science Foundation of China (82260899);

National Natural Science Foundation of China (82274434);

National Youth Qihuang Scholar Program (Guozhong Pharmaceutical Education Letter ［2022］ No.256);

Guangxi Youth Qihuang Scholar Project (Guizhong Medical Science and Education Development ［2023］ No.7)

More Information

Corresponding author: MAO Dewen， mdwboshi2005@163.com （ORCID： 0000-0001-9438-9325）
Received Date: 2024-03-23
Accepted Date: 2024-04-24
Published Date: 2024-12-25

Abstract

Abstract

Hepatic encephalopathy （HE） is a common severe liver disease syndrome in clinical practice and is one of the critical and severe diseases in internal medicine， and more than half of liver failure patients diagnosed with overt HE have a survival time of less than 1 year. A comprehensive analysis of the complex pathogenesis of HE and the development of diagnosis and treatment regimens based on evidence-based medicine are of great importance for alleviating high medical resource consumption， high medical expenses， and high incidence and mortality rates in clinical practice. The latest studies have shown that the intestinal tract and the central nervous system can perform bidirectional continuous interaction and signal transmission and regulate the function of inflammation signals， molecules， cells， and organs， which is known as neuroimmune communication and is highly consistent with the main pathological features of HE. With a focus on the mechanism of neuroimmune communication in HE， this article reviews the association between inflammation signal transduction via the gut-brain axis and neurotransmitter regulation and its role in neuroimmune communication in HE， which provides new ideas for the clinical diagnosis and treatment of HE and the research and development of related drugs.
- Hepatic Encephalopathy,
- Neuroimmunomodulation,
- Gastrointestinal Microbiome

FullText(HTML)

References(39)

References

[1]	RUDLER M, WEISS N, BOUZBIB C, et al. Diagnosis and management of hepatic encephalopathy[J]. Clin Liver Dis, 2021, 25( 2): 393- 417. DOI: 10.1016/j.cld.2021.01.008.
[2]	Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure(2018)[J]. J Clin Hepatol, 2019, 35( 1): 38- 44. DOI: 10.3969/j.issn.1001-5256.2019.01.007. 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版)[J]. 临床肝胆病杂志, 2019, 35( 1): 38- 44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.
[3]	ELSAID MI, RUSTGI VK. Epidemiology of hepatic encephalopathy[J]. Clin Liver Dis, 2020, 24( 2): 157- 174. DOI: 10.1016/j.cld.2020.01.001.
[4]	LIN Y, YAN GJ, FENG F, et al. Association between cholesterol and liver regeneration and its significance and potential value in clinical treatment of liver failure[J]. J Clin Hepatol, 2022, 38( 3): 708- 713. DOI: 10.3969/j.issn.1001-5256.2022.03.044. 林镛, 颜耿杰, 冯逢, 等. 胆固醇与肝再生关系及其在肝衰竭治疗中的意义和潜在价值[J]. 临床肝胆病杂志, 2022, 38( 3): 708- 713. DOI: 10.3969/j.issn.1001-5256.2022.03.044.
[5]	DU YQ, WANG M, HUANG GC, et al. Therapeutic effect of retention enema with compound rhubarb decoction on a rat model of minimal hepatic encephalopathy based on bile acid metabolomics[J]. J Clin Hepatol, 2023, 39( 10): 2348- 2357. DOI: 10.3969/j.issn.1001-5256.2023.10.012. 杜沅沁, 王萌, 黄国初, 等. 基于胆汁酸代谢组学探讨复方大黄煎剂保留灌肠对轻微型肝性脑病大鼠模型的治疗作用[J]. 临床肝胆病杂志, 2023, 39( 10): 2348- 2357. DOI: 10.3969/j.issn.1001-5256.2023.10.012.
[6]	European Association for the Study of the Liver. EASL clinical practice guidelines on the management of hepatic encephalopathy[J]. J Hepatol, 2022, 77( 3): 807- 824. DOI: 10.1016/j.jhep.2022.06.001.
[7]	PUN CK, HUANG HC, CHANG CC, et al. Hepatic encephalopathy: From novel pathogenesis mechanism to emerging treatments[J]. J Chin Med Assoc, 2023, 87( 3): 245- 251. DOI: 10.1097/JCMA.0000000000001041.
[8]	RONALDSON PT, DAVIS TP. Regulation of blood-brain barrier integrity by microglia in health and disease: A therapeutic opportunity[J]. J Cereb Blood Flow Metab, 2020, 40( 1_suppl): S6- S24. DOI: 10.1177/0271678X20951995.
[9]	OCHOA-SANCHEZ R, TAMNANLOO F, ROSE CF. Hepatic encephalopathy: From metabolic to neurodegenerative[J]. Neurochem Res, 2021, 46( 10): 2612- 2625. DOI: 10.1007/s11064-021-03372-4.
[10]	COOPER AJ, PLUM F. Biochemistry and physiology of brain ammonia[J]. Physiol Rev, 1987, 67( 2): 440- 519. DOI: 10.1152/physrev.1987.67.2.440.
[11]	AGIRMAN G, YU KB, HSIAO EY. Signaling inflammation across the gut-brain axis[J]. Science, 2021, 374( 6571): 1087- 1092. DOI: 10.1126/science.abi6087.
[12]	VIDAL-CEVALLOS P, CHÁVEZ-TAPIA NC, URIBE M. Current approaches to hepatic encephalopathy[J]. Ann Hepatol, 2022, 27( 6): 100757. DOI: 10.1016/j.aohep.2022.100757.
[13]	ORZEŁ‍-GAJOWIK K, MILEWSKI K, ZIELIŃSKA M. miRNA-ome plasma analysis unveils changes in blood-brain barrier integrity associated with acute liver failure in rats[J]. Fluids Barriers CNS, 2023, 20( 1): 92. DOI: 10.1186/s12987-023-00484-7.
[14]	SCOTT SA, FU JJ, CHANG PV. Microbial tryptophan metabolites regulate gut barrier function via the aryl hydrocarbon receptor[J]. Proc Natl Acad Sci U S A, 2020, 117( 32): 19376- 19387. DOI: 10.1073/pnas.2000047117.
[15]	KHALIL HMA, ELIWA HA, EL-SHIEKH RA, et al. Ashwagandha(Withania somnifera) root extract attenuates hepatic and cognitive deficits in thioacetamide-induced rat model of hepatic encephalopathy via induction of Nrf2/HO-1 and mitigation of NF-κB/MAPK signaling pathways[J]. J Ethnopharmacol, 2021, 277: 114141. DOI: 10.1016/j.jep.2021.114141.
[16]	ALI SA, DATUSALIA AK. Protective effects of Tinospora cordifolia miers extract against hepatic and neurobehavioral deficits in thioacetamide-induced hepatic encephalopathy in rats via modulating hyperammonemia and glial cell activation[J]. J Ethnopharmacol, 2024, 323: 117700. DOI: 10.1016/j.jep.2023.117700.
[17]	CRYAN JF, O’RIORDAN KJ, COWAN CSM, et al. The microbiota-gut-brain axis[J]. Physiol Rev, 2019, 99( 4): 1877- 2013. DOI: 10.1152/physrev.00018.2018.
[18]	XU CL, LEE SK, ZHANG DC, et al. The gut microbiome regulates psychological-stress-induced inflammation[J]. Immunity, 2020, 53( 2): 417- 428. DOI: 10.1016/j.immuni.2020.06.025.
[19]	LOUVEAU A, HERZ J, ALME MN, et al. CNS lymphatic drainage and neuroinflammation are regulated by meningeal lymphatic vasculature[J]. Nat Neurosci, 2018, 21( 10): 1380- 1391. DOI: 10.1038/s41593-018-0227-9.
[20]	JAMESON KG, OLSON CA, KAZMI SA, et al. Toward understanding microbiome-neuronal signaling[J]. Mol Cell, 2020, 78( 4): 577- 583. DOI: 10.1016/j.molcel.2020.03.006.
[21]	JIA W, RAJANI C, KADDURAH-DAOUK R, et al. Expert insights: The potential role of the gut microbiome-bile acid-brain axis in the development and progression of Alzheimer’s disease and hepatic encephalopathy[J]. Med Res Rev, 2020, 40( 4): 1496- 1507. DOI: 10.1002/med.21653.
[22]	LIU T, ZHANG LY, JOO D, et al. NF-κB signaling in inflammation[J]. Signal Transduct Target Ther, 2017, 2: 17023. DOI: 10.1038/sigtrans.2017.23.
[23]	ESSAM RM, SAADAWY MA, GAMAL M, et al. Lactoferrin averts neurological and behavioral impairments of thioacetamide-induced hepatic encephalopathy in rats via modulating HGMB1/TLR-4/MyD88/Nrf2 pathway[J]. Neuropharmacology, 2023, 236: 109575. DOI: 10.1016/j.neuropharm.2023.109575.
[24]	KIGERL KA, LAI WM, WALLACE LM, et al. High mobility group box-1(HMGB1) is increased in injured mouse spinal cord and can elicit neurotoxic inflammation[J]. Brain Behav Immun, 2018, 72: 22- 33. DOI: 10.1016/j.bbi.2017.11.018.
[25]	YOU XH, WANG LX, FENG DC. Relationship of the intestinal flora and irritable bowel syndrome sub-typing with the functional changes in the neuroendocrine axis[J]. J Clin Exp Med, 2022, 21( 15): 1667- 1670. DOI: 10.3969/j.issn.1671-4695.2022.15.027. 游先辉, 王利霞, 冯大超. 肠道菌群和肠易激综合征分型与神经内分泌轴功能变化的关系研究[J]. 临床和实验医学杂志, 2022, 21( 15): 1667- 1670. DOI: 10.3969/j.issn.1671-4695.2022.15.027.
[26]	PENNY HA, DOMINGUES RG, KRAUSS MZ, et al. Rhythmicity of intestinal IgA responses confers oscillatory commensal microbiota mutualism[J]. Sci Immunol, 2022, 7( 75): eabk2541. DOI: 10.1126/sciimmunol.abk2541.
[27]	ROJAS OL, PRÖBSTEL AK, PORFILIO EA, et al. Recirculating intestinal IgA-producing cells regulate neuroinflammation via IL-10[J]. Cell, 2019, 176( 3): 610- 624. DOI: 10.1016/j.cell.2018.11.035.
[28]	BONAZ B, BAZIN T, PELLISSIER S. The vagus nerve at the interface of the microbiota-gut-brain axis[J]. Front Neurosci, 2018, 12: 49. DOI: 10.3389/fnins.2018.00049.
[29]	BLUTHÉ RM, MICHAUD B, KELLEY KW, et al. Vagotomy blocks behavioural effects of interleukin-1 injected via the intraperitoneal route but not via other systemic routes[J]. Neuroreport, 1996, 7( 15-17): 2823- 2827. DOI: 10.1097/00001756-199611040-00083.
[30]	MCVEY NEUFELD KA, BIENENSTOCK J, BHARWANI A, et al. Oral selective serotonin reuptake inhibitors activate vagus nerve dependent gut-brain signalling[J]. Sci Rep, 2019, 9( 1): 14290. DOI: 10.1038/s41598-019-50807-8.
[31]	MORAIS LH, SCHREIBER HL ^4th. MAZMANIAN SK The gut microbiotabrain axis in behaviour and brain disorders[J]. Nat Rev Microbiol, 2021, 19( 4): 241- 255. DOI: 10.1038/s41579-020-00460-0.
[32]	MARTÍNEZ-LOZADA Z, ORTEGA A. Glutamatergic transmission: A matter of three[J]. Neural Plast, 2015, 2015: 787396. DOI: 10.1155/2015/787396.
[33]	CABRERA-PASTOR A, LLANSOLA M, MONTOLIU C, et al. Peripheral inflammation induces neuroinflammation that alters neurotransmission and cognitive and motor function in hepatic encephalopathy: Underlying mechanisms and therapeutic implications[J]. Acta Physiol(Oxf), 2019, 226( 2): e13270. DOI: 10.1111/apha.13270.
[34]	KOSENKOV AM, GAIDIN SG, SERGEEV AI, et al. Fast changes of NMDA and AMPA receptor activity under acute hyperammonemia in vitro[J]. Neurosci Lett, 2018, 686: 80- 86. DOI: 10.1016/j.neulet.2018.08.054.
[35]	CAULI O, GONZÁLEZ-USANO A, CABRERA-PASTOR A, et al. Blocking NMDA receptors delays death in rats with acute liver failure by dual protective mechanisms in kidney and brain[J]. NeuroMolecular Med, 2014, 16( 2): 360- 375. DOI: 10.1007/s12017-013-8283-5.
[36]	KULLMANN DM, RUIZ A, RUSAKOV DM, et al. Presynaptic, extrasynaptic and axonal GABAA receptors in the CNS: Where and why?[J]. Prog Biophys Mol Biol, 2005, 87( 1): 33- 46. DOI: 10.1016/j.pbiomolbio.2004.06.003.
[37]	FRIED DE, WATSON RE, ROBSON SC, et al. Ammonia modifies enteric neuromuscular transmission through glial γ-aminobutyric acid signaling[J]. Am J Physiol Gastrointest Liver Physiol, 2017, 313( 6): G570- G580. DOI: 10.1152/ajpgi.00154.2017.
[38]	MA FH, YANG L, SUN ZR, et al. Neurotransmitter-derived lipidoids(NT-lipidoids) for enhanced brain delivery through intravenous injection[J]. Sci Adv, 2020, 6( 30): eabb4429. DOI: 10.1126/sciadv.abb4429.
[39]	TERSTAPPEN GC, MEYER AH, BELL RD, et al. Strategies for delivering therapeutics across the blood-brain barrier[J]. Nat Rev Drug Discov, 2021, 20( 5): 362- 383. DOI: 10.1038/s41573-021-00139-y.

Relative Articles

[1]	Aiping TIAN, Yongfeng YANG. Diagnosis of nonalcoholic fatty liver disease: The importance of pathology[J]. Journal of Clinical Hepatology, 2023, 39(3): 491-497. doi: 10.3969/j.issn.1001-5256.2023.03.002
[2]	Shengnan DU, Jingjing GAO, Tao WANG, Yuanye JIANG, Qin CAO. Value of circular RNA in the diagnosis and treatment of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(11): 2684-2688. doi: 10.3969/j.issn.1001-5256.2021.11.043
[3]	Cong TONG, Yanian LI, Da GU, Xiang'an ZHAO, Xiaoxing XIANG. The association between obesity measurement indices and nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(10): 2465-2468. doi: 10.3969/j.issn.1001-5256.2021.10.044
[4]	Xiangqian HUANG, Xiaomeng YAN, Mingda ZHANG, Jing WU, Jianhong CHEN. Association between nonalcoholic fatty liver disease and colorectal neoplasms[J]. Journal of Clinical Hepatology, 2021, 37(12): 2947-2950. doi: 10.3969/j.issn.1001-5256.2021.12.045
[5]	Jiahe ZHAO, Xinyu MA, Jingya XU, Tingting DUAN, Chunlei ZHANG, Baolong LI. Research advances in related factors for autophagy in the regulation of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(7): 1713-1717. doi: 10.3969/j.issn.1001-5256.2021.07.050
[6]	Gao Xin. New thoughts about renaming nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(6): 1201-1204. doi: 10.3969/j.issn.1001-5256.2020.06.001
[7]	A RuHan, Jia HaiYan, Ding YanHua, Niu JunQi. Research advances in nonalcoholic fatty liver disease in lean individuals[J]. Journal of Clinical Hepatology, 2020, 36(5): 1154-1159. doi: 10.3969/j.issn.1001-5256.2020.05.046
[8]	Li WenYi, Yuan ChengMin. Research advances in integrated traditional Chinese and Western medicine therapy for nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(4): 919-923. doi: 10.3969/j.issn.1001-5256.2020.04.047
[9]	YU Di, YANG XuYao, ZHAO JinHan, CHUAN LiXue, CHANG Jiang. Association between anxiety and nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(11): 2589-2592. doi: 10.3969/j.issn.1001-5256.2020.11.043
[10]	WANG Xin, HU YiYang, LIU Ping, FENG Qin. Association between hypertension and nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(11): 2584-2588. doi: 10.3969/j.issn.1001-5256.2020.11.042
[11]	Yang XuYao, Yu Di, Zhao JinHan, Chuan LiXue, Chang Jiang. Association between nonalcoholic fatty liver disease and depression[J]. Journal of Clinical Hepatology, 2020, 36(1): 201-204. doi: 10.3969/j.issn.1001-5256.2020.01.048
[12]	Ceng Jing, Fan JianGao. Clinical significance of renaming nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(6): 1205-1207. doi: 10.3969/j.issn.1001-5256.2020.06.002
[13]	Yao ChengZi, Feng Gong, Yu WenSi, Du Huan, Mi Man. Risk factors for the development and progression of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(2): 433-436. doi: 10.3969/j.issn.1001-5256.2020.02.044
[14]	Jiang YuZi, Nie HongMing, Wang Rong. Research advances in the pathogenesis of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2019, 35(11): 2588-2591. doi: 10.3969/j.issn.1001-5256.2019.11.044
[15]	Gong Hang, Li LiangPing. Noninvasive diagnosis of progressive nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2019, 35(2): 406-410. doi: 10.3969/j.issn.1001-5256.2019.02.038
[16]	Zhao LiQiong, Li LiangPing. Independent association between sarcopenia and nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2019, 35(6): 1377-1379. doi: 10.3969/j.issn.1001-5256.2019.06.044
[17]	Chu PeiLing, Wang Qi, Guo XiaoQing, Liu JinChun. Association between chemokines and nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2019, 35(7): 1626-1628. doi: 10.3969/j.issn.1001-5256.2019.07.044
[18]	Suo YuHong, Liu JinChun. Research advances in the treatment of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2018, 34(10): 2232-2236. doi: 10.3969/j.issn.1001-5256.2018.10.038
[19]	Xie Xiao, Lu LunGen. Potential therapeies for nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2017, 33(12): 2439-2443. doi: 10.3969/j.issn.1001-5256.2017.12.042
[20]	Feng Gong, Niu ChunYan. Advances in the treatment of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2017, 33(12): 2433-2438. doi: 10.3969/j.issn.1001-5256.2017.12.041

Supplements(0)

Cited By

Cited by

Periodical cited type(4)

1.	杨宁宁，郑振，张然，武钰翔，王祺. 血清TSP2、APRI在2型糖尿病合并非酒精性脂肪性肝病诊断中的临床价值. 临床和实验医学杂志. 2025(04): 385-389 .
2.	宋传玉，李庆荣，李旭，孙富勇，贾磊. 枸杞多糖缓解非酒精性脂肪肝大鼠肝脏纤维化和肝脏炎症的研究表达水平. 宁夏医学杂志. 2025(02): 93-96+185 .
3.	贺艳，柯洪琴，李洪亮，朱建勇，赵利军，于慧斌. 美罗培南相关肝损伤的影响因素及其预测价值. 临床肝胆病杂志. 2025(03): 506-512 . 本站查看
4.	江小丽，李春汉，林丽雯，周俊铷，叶润杰，胡亦懿，谭力学. 基于瞬时弹性成像与血清学指标无创诊断肝纤维化模型的建立与评估. 现代消化及介入诊疗. 2024(08): 975-978 .

Other cited types(0)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(2)

Get Citation

PDF

XML

Article Metrics

Article views (427) PDF downloads(39)